Cell-based therapy for Crohn’s disease: time to consider optimization

Amy Lightner

Research output: Contribution to journalArticle

Abstract

Cell-based therapies for the treatment of perianal Crohn’s disease have well-established safety profiles and improved efficacy compared with conventional therapy. However, stem cells are not a homogeneous product and questions remain before we can optimize clinical trials of these treatments and achieve best patient outcomes.

Original languageEnglish (US)
JournalNature Reviews Gastroenterology and Hepatology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Cell- and Tissue-Based Therapy
Crohn Disease
Stem Cells
Therapeutics
Clinical Trials
Safety

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Cell-based therapy for Crohn’s disease : time to consider optimization. / Lightner, Amy.

In: Nature Reviews Gastroenterology and Hepatology, 01.01.2018.

Research output: Contribution to journalArticle

@article{d239f2c54cfd4f6685253d7069e499f0,
title = "Cell-based therapy for Crohn’s disease: time to consider optimization",
abstract = "Cell-based therapies for the treatment of perianal Crohn’s disease have well-established safety profiles and improved efficacy compared with conventional therapy. However, stem cells are not a homogeneous product and questions remain before we can optimize clinical trials of these treatments and achieve best patient outcomes.",
author = "Amy Lightner",
year = "2018",
month = "1",
day = "1",
doi = "10.1038/s41575-018-0095-5",
language = "English (US)",
journal = "Nature Reviews Gastroenterology and Hepatology",
issn = "1759-5045",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Cell-based therapy for Crohn’s disease

T2 - time to consider optimization

AU - Lightner, Amy

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Cell-based therapies for the treatment of perianal Crohn’s disease have well-established safety profiles and improved efficacy compared with conventional therapy. However, stem cells are not a homogeneous product and questions remain before we can optimize clinical trials of these treatments and achieve best patient outcomes.

AB - Cell-based therapies for the treatment of perianal Crohn’s disease have well-established safety profiles and improved efficacy compared with conventional therapy. However, stem cells are not a homogeneous product and questions remain before we can optimize clinical trials of these treatments and achieve best patient outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85058189049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058189049&partnerID=8YFLogxK

U2 - 10.1038/s41575-018-0095-5

DO - 10.1038/s41575-018-0095-5

M3 - Article

C2 - 30532061

AN - SCOPUS:85058189049

JO - Nature Reviews Gastroenterology and Hepatology

JF - Nature Reviews Gastroenterology and Hepatology

SN - 1759-5045

ER -